Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

2PET

Lutheran glycoprotein, N-terminal domains 1 and 2.

2PET の概要
エントリーDOI10.2210/pdb2pet/pdb
分子名称Lutheran blood group glycoprotein (2 entities in total)
機能のキーワードimmunoglobulin superfamily., cell adhesion
由来する生物種Homo sapiens (human)
細胞内の位置Membrane; Single-pass type I membrane protein: P50895
タンパク質・核酸の鎖数1
化学式量合計25647.83
構造登録者
Burton, N.,Brady, R.L. (登録日: 2007-04-03, 公開日: 2007-12-04, 最終更新日: 2024-11-13)
主引用文献Mankelow, T.J.,Burton, N.,Stefansdottir, F.O.,Spring, F.A.,Parsons, S.F.,Pedersen, J.S.,Oliveira, C.L.,Lammie, D.,Wess, T.,Mohandas, N.,Chasis, J.A.,Brady, R.L.,Anstee, D.J.
The Laminin 511/521-binding site on the Lutheran blood group glycoprotein is located at the flexible junction of Ig domains 2 and 3.
Blood, 110:3398-3406, 2007
Cited by
PubMed Abstract: The Lutheran blood group glycoprotein, first discovered on erythrocytes, is widely expressed in human tissues. It is a ligand for the alpha5 subunit of Laminin 511/521, an extracellular matrix protein. This interaction may contribute to vaso-occlusive events that are an important cause of morbidity in sickle cell disease. Using x-ray crystallography, small-angle x-ray scattering, and site-directed mutagenesis, we show that the extracellular region of Lutheran forms an extended structure with a distinctive bend between the second and third immunoglobulin-like domains. The linker between domains 2 and 3 appears to be flexible and is a critical determinant in maintaining an overall conformation for Lutheran that is capable of binding to Laminin. Mutagenesis studies indicate that Asp312 of Lutheran and the surrounding cluster of negatively charged residues in this linker region form the Laminin-binding site. Unusually, receptor binding is therefore not a function of the domains expected to be furthermost from the plasma membrane. These studies imply that structural flexibility of Lutheran may be essential for its interaction with Laminin and present a novel opportunity for the development of therapeutics for sickle cell disease.
PubMed: 17638854
DOI: 10.1182/blood-2007-06-094748
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.7 Å)
構造検証レポート
Validation report summary of 2pet
検証レポート(詳細版)ダウンロードをダウンロード

248636

件を2026-02-04に公開中

PDB statisticsPDBj update infoContact PDBjnumon